Standard BioTools Inc. (LAB)

2.4800 0.0000 (0.00%) 收市：04:00PM EDT

Standard BioTools Inc.

2 Tower Place
Suite 2000
South San Francisco, CA 94080
United States
650 266 6000
https://www.standardbio.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 534

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Michael Egholm Ph.D.	President, CEO & Director	1.37M	無	1963
Mr. Jeffrey G. Black	Chief Financial Officer	687.06k	無	1969
Mr. Hanjoon Kim	Chief Operating Officer	723k	無	1971
Dr. Shane Bowen Ph.D.	Chief Technology Officer	無	無	無
David Holmes	Investor Relations	無	無	無
Mr. Adam Taich	Chief Strategy Officer	無	無	1976

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

公司管治

截至 2024年6月1日 止，Standard BioTools Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：5；董事會：8；股東權利：9；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。